Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland

Agata Czarnowska 1*, Joanna Tarasiuk 1, Olga Zajkowska 2, Marcin Wnuk 3, Monika Marona 4, Konrad Rejdak 4, Beata Lech 5, Małgorzata Popiel 6, Iwona Rościszewska-Żukowska 7, Adam Perenc 8, Halina Bartosik-Psujek 9, Mariola Świderek-Matysiak 7, Małgorzata Siger 7, Agnieszka Ciach 7, Agata Walczak 7, Anna Juriewicz 7, Mariusz Stasiolek 7, Karolina Kania 8, Klara Dyczkowska 2, Alicja Kalinowska-Łyszczarz 9, Weronika Galus 10, Anna Walawska-Hrycek 10, Ewa Krzysztanek 10, Justyna Chojdał-Łukasiewicz 11, Jakub Ubysz 11, Anna Pokrzyśko-Dragan 11, Katarzyna Kapica-Topczewska 1, Monika Chorąży 1, Marcin Bazyłewicz 1, Anna Mironczuk 1, Joanna Kulikowska 1, Jan Kochanowicz 1, Marta Białek 12, Małgorzata Stolarz 12, Katarzyna Kubicka-Bączyk 13, Natalia Niedziela 13, Paweł Warmus 13, Monika Adamczyk-Sowa 13, Aleksandra Podlecka-Piętowska 14, Monika Nojszewska 14, Beata Zakrzewska-Pniewska 14, Elżbieta Jasirski 15, 16, Jacek Zaborski 15, 16, Jacek Zwiernik 19, 20, Beata Zwiernik 21, 22, Andrzej Potemkowski 23, Waldemar Brola 24† and Alina Kulakowska 1†

OPEN ACCESS

Edited by:
Omid Mirmozayeeb,
Istfahan University of Medical Sciences, Iran

Reviewed by:
Abdorrea Naser Moghadasi,
Tehran University of Medical Sciences, Iran
Mahdi Barzegar,
Istfahan University of Medical Sciences, Iran

*Correspondence:
Agata Czarnowska
zajkowskaagata@gmail.com

†These authors have contributed equally to this work and share last authorship

Specialty section:
This article was submitted to
Multiple Sclerosis and Neuroimmunology,
a section of the journal
Frontiers in Neurology

Background and Objectives: Since vaccination against COVID-19 is available for over a year and the population of immunized individuals with autoimmune disorders is higher than several months before, an evaluation of safety and registered adverse events can be made. We conducted a large study of side effects following the COVID-19 vaccine among patients with multiple (MS) sclerosis treated with disease-modifying therapies (DMTs) and analyzed factors predisposing for particular adverse events.
**Methods:** We gathered data of individuals with MS treated with DMTs from 19 Polish MS Centers, who reported at least one adverse event following COVID-19 vaccination. The information was obtained by neurologists using a questionnaire. The same questionnaire was used at all MS Centers. To assess the relevance of reported adverse events, we used Fisher’s exact test, t-test, and U-Mann-Whitney test.

**Results:** A total of 1,668 patients with MS and reports of adverse events after COVID-19 vaccination were finally included in the study. Besides one case marked as “red flag”, all adverse events were classified as mild. Pain at the injection site was the most common adverse event, with a greater frequency after the first dose. Pain at the injection site was significantly more frequent after the first dose among individuals with a lower disability (EDSS ≤2). The reported adverse events following immunization did not differ over sex. According to age, pain at the injection site was more common among individuals between 30 and 40 years old, only after the first vaccination dose. None of the DMTs predisposed for particular side effects.

**Conclusions:** According to our findings, vaccination against COVID-19 among patients with MS treated with DMTs is safe. Our study can contribute to reducing hesitancy toward vaccination among patients with MS.

**Keywords:** multiple sclerosis, vaccination, SARS-CoV-2, COVID-19, side effects

**INTRODUCTION**

The long-term impact of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection on individuals with autoimmune disorders is unknown. Among patients with multiple sclerosis (MS), the course of the infection can be severe in those with a higher level of disability, comorbid diseases, older, and on high effective therapies (1).

In general, vaccination is recommended for individuals with MS. Systemic infection can worsen the course of MS, so prevention is advisable. Most vaccines are considered safe for patients under disease-modifying therapies (DMTs). However, live vaccines are contraindicated under immunosuppressive treatment in most cases (2).

The first vaccines against coronavirus disease 2019 (COVID-19) were approved by the end of 2020. Their high effectiveness was reported in early studies. The mortality and hospitalization rate of SARS-CoV-2 infection is significantly lower in vaccinated persons (3, 4). Throughout the COVID-19 pandemic, diverse variants of SARS-CoV-2 have emerged. The latest variant (Omicron) seems to be more infectious than the original virus (5). The effectiveness of vaccination varies across virus variants and is still under investigation. However, a beneficial role of vaccination is suggested against old and novel variants. The proposed mechanism behind this is the immunological T cell memory induced by vaccination to cross-recognize different variants (6). Therefore, vaccination against COVID-19 is highly recommended, especially for those with autoimmune and other comorbid diseases (7).

Numerous adverse events were reported after the COVID-19 vaccination. However, the overwhelming majority of side effects are mild and self-limiting. In rare cases, serious post-vaccine incidents were observed, including neurological side effects (8).

Here we report adverse events after COVID-19 vaccination among individuals with multiple sclerosis treated with different disease-modifying therapies in Poland and identify any predisposing factors for the occurrence of side effects.

**MATERIALS AND METHODS**

The Multiple Sclerosis and Neuroimmunology Section of the Polish Neurological Society published an announcement about the study at www.ptneuro.pl, and every MS Center in Poland was invited to participate. Finally, participants were recruited from 19 Polish MS Centers. The data was obtained by neurologists using a questionnaire. The same questionnaire was used at all MS Centers (available in Supplementary Materials). Patients were recruited to the study during standard or unplanned visits at a particular MS Center or over the telephone.

We included individuals who had any adverse event after COVID-19 vaccination and confirmed diagnosis of MS according to 2010 and 2017 McDonald criteria. Disability was assessed by the Expanded Disability Status Scale (EDSS). All patients were treated with one of the DMTs available in Poland (interferon, glatiramer acetate, teriflunomide, dimethyl fumarate, fingolimod, alemtuzumab, cladribine, natalizumab, or ocrelizumab).

We collected patient demographics, data regarding specific features of multiple sclerosis, information about vaccination against SARS-CoV-2, presence of adverse events after vaccination), and information regarding relapses following
immunization or worsening of MS symptomatology. Incidence classified as relapse must have had a clear monophasic course, objective findings typical of multiple sclerosis verified by a neurologist, lasted over 24 h, and were not related to fever or infection. Gathered data included side effects after the first or second dose of different vaccines. The analysis did not include side effects after the third dose, as the observation time would be insufficient and the number of patients too little.

Categorical variables were characterized by frequency and percentage. Continuous variables were reported by their median, mean value, and interquartile range. For statistical comparisons, the \( \chi^2 \) test of homogeneity of odds was calculated. To assess the relevance of reported adverse events, we used Fisher’s exact test, \( t \)-test, and \( U \)-Mann-Whitney test.

All calculations were performed using STATA 15 software (StataCorp 2017) (7).

The study was approved (approval No. 62/2021) by the Bioethics Committee at Collegium Medicum, Jan Kochanowski University in Kielce, Poland.

### RESULTS

A total of 1,668 individuals with MS and reports of adverse events after COVID-19 vaccination were included in the study. Among participating MS Centers 3,264 patients were vaccinated with at least one dose. Therefore, the percentage of individuals reporting any adverse events was 51% and the percentage of patients denying any side effects was 49%. Thirty-seven patients with missing data were excluded. Demographic and clinical data regarding features of multiple sclerosis are presented in Table 1. The average observation time was 7 months (range: 1–12 months).

The distribution of vaccines against \( SARS-CoV-2 \) administered among the cohort was as follows: 1,215 (72.84%) patients immunized with the BioNTech-Pfizer vaccine, 223 (13.37%) with the Oxford-Astra Zeneca vaccine, 155 (9.29%) with the Moderna vaccine, and 75 (4.5%) with the Johnson & Johnson vaccine. More than three-quarters (77.34%) of individuals were administered vaccines using genetically engineered mRNA to induce an immune response.

### Table 1 | Demographics and clinical characteristics of patients with MS who presented with side effects following vaccination against \( SARS-CoV-2 \).

|                                    | N   | (%) | Mean | Median | IQR | SD  |
|------------------------------------|-----|-----|------|--------|-----|-----|
| Study population                   | 1,668 | 100 |      |        |     |     |
| Sex                                |      |     |      |        |     |     |
| Female                             | 1,209 |    72.48 | 41.88 | 42 | 16 | 11.07 |
| Male                               | 459 |    27.52 | 41.49 | 41 | 16 | 10.68 |
| Whole study population age         |      |     | 41.88 | 42 | 16 | 11.07 |
| Female age                         |      |     | 42.03 | 42 | 16 | 11.21 |
| Male age                           |      |     | 41.49 | 41 | 16 | 10.68 |
| Disease course                     |      |     |      |        |     |     |
| RRMS                               | 1,585 |    95.02 | 2.36 | 2 | 2.5 | 1.48 |
| SPMS                               | 42 |    2.52 | 3.94 | 3 | 3.44 | 3.34 |
| PPMS                               | 41 |    2.46 | 3.94 | 3 | 3.44 | 3.34 |
| EDSS ≤ 2                           | 917 |    54.98 | 5.98 | 5.88 | 5.88 |
| EDSS > 2                           | 658 |    39.44 | 6.44 | 6.03 | 6.03 |
| Disease duration                   |      |     | 9.44 | 8 | 9 | 6.34 |
| DMTs                               |      |     |      |        |     |     |
| Interferon beta                    | 377 |    22.6 | 22.6 | 22.6 | 22.6 | 22.6 |
| Glatiramer acetate                 | 134 |    8.03 | 8.03 | 8.03 | 8.03 | 8.03 |
| Dimethyl fumarate                  | 665 |    39.87 | 39.87 | 39.87 | 39.87 | 39.87 |
| Teriflunomide                      | 168 |    10.07 | 10.07 | 10.07 | 10.07 | 10.07 |
| Fingolimod                         | 74 |    4.44 | 4.44 | 4.44 | 4.44 | 4.44 |
| Natalizumab                        | 105 |    6.29 | 6.29 | 6.29 | 6.29 | 6.29 |
| Ocrelizumab                        | 77 |    4.62 | 4.62 | 4.62 | 4.62 | 4.62 |
| Cladribine                         | 14 |    0.84 | 0.84 | 0.84 | 0.84 | 0.84 |
| Alemtuzumab                        | 10 |    0.6 | 0.6 | 0.6 | 0.6 | 0.6 |
| Mitoxantrone                       | 6 |    0.36 | 0.36 | 0.36 | 0.36 | 0.36 |
| Others                             | 38 |    2.28 | 2.28 | 2.28 | 2.28 | 2.28 |

AMS, multiple sclerosis; SD, standard deviation; IQR, interquartile range; RRMS, relapsing-remitting multiple sclerosis; PPMS, primary progressive multiple sclerosis; SPMS, secondary progressive multiple sclerosis; EDSS, the expanded disability status scale; DMTs, disease-modifying therapies.
Czarnowska et al. Multiple Sclerosis and COVID-19 Vaccination

FIGURE 1 | The distribution of adverse events reported in individuals with MS treated with DMTs in Poland.

The reported adverse events were almost exclusively mild. The distribution of particular side effects among the cohort is presented in Figure 1. The most common, with a greater frequency after the first dose, was pain at the injection site. Fever/chills/flu-like symptoms, fatigue, headache, malaise, and muscle/joint pain were more often present after the second dose. In the majority of cases, the reported symptoms were self-limiting. The adverse events resolved within 7 days in 98.3% of patients after the first dose and 97.6% after the second dose. The proportion of most common adverse events following particular vaccines is shown in Table 2. All differences were statistically significant.

The mRNA vaccines significantly predisposed for developing pain at the injection site in comparison to vaccines using non-replicating viral vectors (Oxford-Astra Zeneca vaccine; Johnson & Johnson vaccine) \((p = 0.001)\). However, being administered with vector vaccines increased propensity for fever, headache, fatigue, skin lesion at the injection site, and muscle/joint pain following immunization \((p = 0.000, p = 0.000, p = 0.001, p = 0.004; p = 0.000, \text{respectively})\).

Generally, the observed side effects were not multisymptomatic. After the first dose, 844 (50.6%) individuals had one adverse event and 655 (41.64%) after the second dose. The number of reported adverse events by individual patients is shown in Figure 2.

Only one adverse event was classified as “Red-Flag”. It was a pro-thrombotic incidence in a 42 years old female patient 2 weeks after the first dose of the Oxford-Astra Zeneca vaccine. The patient complained of chest pain, the laboratory finding showed elevated D-dimers level, but pulmonary embolism was excluded. Currently, the patients fell well and further diagnostics did not confirm any thromboembolism. Three patients had anaphylactic reactions immediately after immunization (one individual after both doses). There were no fatal outcomes following vaccination.

None of the DMTs significantly predisposed for particular adverse events or longer duration of side effects. However, the sample size for cladribine, alemtuzumab, and mitoxantrone was insufficient for statistical analysis.

The reported adverse events following immunization did not differ between sex. According to age, pain at the injection site was more common among individuals between 30 and 40 years old, only after the first vaccination dose \((p = 0.001)\). The proportion of most common adverse events divided by age is shown in Figures 3A,B. The mean duration of the disease was similar for all side effects, there were none relevant differences.

Pain at the injection site was significantly more frequent after the first dose among individuals with a lower disability \((\text{EDSS} \leq 2)\) \((p = 0.027)\). However, a headache was the dominant adverse event after the first dose in individuals with moderate disability \((\text{EDSS} 3–4)\) \((p = 0.005)\). The proportion of patients with the most common adverse events divided by EDSS is shown in Figures 4A,B.

Among individuals with RRMS, 4.42% of patients (70 people) had relapses up to 3 months before vaccination. After immunization (up to 3 months), 67 patients (4.02%) had
TABLE 2 | The proportion of most common side effects after particular vaccines administered among the cohort.

|                          | Pain at the injection site (%) | Skin lesion at the injection site (%) | Fever, chills, flu-like symptoms (%) | Fatigue (%) | Headache (%) | Muscle pain/Joint pain (%) | Malaise (%) |
|--------------------------|-------------------------------|--------------------------------------|-------------------------------------|-------------|--------------|---------------------------|-------------|
| **First dose**           |                               |                                      |                                     |             |              |                           |             |
| BioNTech, Pfizer vaccine | 68.89                         | 4.86                                 | 20.08                               | 12.59       | 10.04        | 7.16                      | 7.08        |
| Oxford, Astra Zeneca Vaccine | 60.99                        | 11.21                                | 43.05                               | 22.42       | 22.42        | 17.04                     | 20.18       |
| Moderna vaccine          | 64.52                         | 15.48                                | 27.74                               | 16.13       | 16.77        | 10.97                     | 10.97       |
| Johnson & Johnson vaccine | 49.33                         | 10.67                                | 48                                  | 17.33       | 17.33        | 12                        | 10.67       |
| Pearson chi²             | 0.001                         | 0.000                                | 0.000                               | 0.001       | 0.000        | 0.000                     | 0.000       |
| Fisher’s exact p-value   | 0.001                         | 0.000                                | 0.000                               | 0.002       | 0.000        | 0.000                     | 0.000       |
| **Second dose**          |                               |                                      |                                     |             |              |                           |             |
| BioNTech, Pfizer vaccine | 54.98                         | 4.53                                 | 26.42                               | 14.73       | 10.29        | 9.3                       | 9.71        |
| Oxford, Astra Zeneca Vaccine | 36.77                        | 8.97                                 | 26.01                               | 16.14       | 24.66        | 12.56                     | 10.76       |
| Moderna vaccine          | 52.26                         | 8.39                                 | 50.32                               | 24.52       | 20           | 24.52                     | 24.52       |
| Pearson chi²             | 0.000                         | 0.002                                | 0.000                               | 0.000       | 0.000        | 0.000                     | 0.000       |
| Fisher’s exact p-value   | 0.000                         | 0.002                                | 0.000                               | 0.000       | 0.000        | 0.000                     | 0.000       |

**FIGURE 2** | The number of adverse events reported by individual patients with MS treated with DMTs in Poland.

relapsed, but only 22.39% of them within the first 21 days. In 29 cases (1.74%), the worsening occurred after the first dose and in 38 (2.28%) after the second dose. Magnetic resonance imaging (MRI) was not routinely performed.

**DISCUSSION**

The real-world data regarding vaccination against SARS-CoV-2 among individuals with autoimmune disorders is limited. This study analyzes the range of adverse events following the COVID-19 vaccine reported in patients with multiple sclerosis treated with DMTs.

In our observation, almost all reported adverse events were mild and self-limiting. The most common were pain at the injection site, fever/chills/flu-like symptoms, and fatigue. A similar range and frequency of adverse events were found in clinical trials evaluating COVID-19 vaccinations in general population (9). Pain at the injection site after the first dose
Czarnowska et al. Multiple Sclerosis and COVID-19 Vaccination

FIGURE 3 | (A) The proportion (%) of most common adverse events according to age after the first dose. (B) The proportion (%) of most common adverse events according to age after the second dose.

of vaccination was more common for individuals with lower disability and patients under 40 years old. The same observations were made on a smaller cohort of people with SM by Achiron et al. (10). In several other studies, based on the general population, also younger patients reported any adverse events more often (11, 12). Therefore, the shift toward younger patients may not be related to the coexistence of autoimmune diseases.

Three patients had developed anaphylactic reactions immediately after immunization. Only one patient had a prothrombotic “Red-Flag” (chest pain, elevated D-dimers level) without a final diagnosis of any embolism.

Interestingly, in clinical trials of COVID-19 vaccines, the percentage of adverse events in the placebo group was quite high (approximately one-third). The most frequent were headaches and fatigue (13). It is important to acknowledge the fact, as the mentioned symptoms were also common among patients with MS and, in some cases, might be related to other factors (e.g., anxiety related to the safety of the vaccine).

The occurrence of relapses following vaccination was very low in our cohort and not higher in comparison to the 3 month period before immunization. There are case reports in the literature showing a temporal relation between the COVID-19 vaccine and relapse (14). However, the greater frequency of relapses following vaccination against SARS-CoV-2 has not been observed in our study or other studies conducted on a larger number of patients, including the third dose (10, 14, 15).

None of the DMTs among the cohort were predisposed to a particular adverse event. There was no difference between monoclonal antibodies, sphingosine-1-phosphate receptor modulators, and other therapies in terms of type or the duration...
of reported side effects. Patients with MS were vaccinated in Poland, keeping a time interval between the administration of certain DMTs according to guidelines, consistent with international consensus (16). The vast majority of our cohort was administered vaccines based on mRNA. Therefore, based on our findings, we can conclude that mRNA vaccines are safe, even on high-efficacy therapies. Among individuals immunized with the use of non-replicating viral vectors, the reported adverse events were also mild, but as the number of patients was much smaller in comparison to patients administered with mRNA vaccines, a larger observation is required to draw conclusions.

The results of our study provide an argument for proimmunization among hesitating individuals. As we know from several studies, there are multiple issues holding patients back from getting vaccinated (17, 18). Most are related to the novelty of the vaccination and concerns about its safety. Also, their effectiveness is constantly undermined by false information on the Internet and social media (19). This creates a big challenge for health workers worldwide. Most clinical trials are based on the general population. Therefore, our study proving vaccination safety among individuals with MS can be a convincing tool for these particular patients.

There are several limitations to our study. Although the study included a large representation of patients with MS treated with DMTs in Poland, the total number of individuals treated with DMTs is much higher. We did not include non-treated with DMTs patients and those with a high level of disability (EDSS >8). Furthermore, the representation of different types of MS is unequal in the cohort as mostly patients with RRMS are included. Finally, the reports of adverse events were in most cases retrospective and based, besides relapses, on
subjective assessment of the patient, so it might be imprecise in some individuals.

CONCLUSIONS

The reason for COVID-19 vaccination hesitancy is multifactorial. However, there are genuine fears of potential adverse events, especially among individuals with autoimmune diseases. Our study demonstrates the safety of vaccination against SARS-CoV-2 among patients with MS treated with DMTs. Almost all reported symptoms were mild and self-limiting, some were more frequent in younger patients and with lower EDSS.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The name of the repository and accession number can be found below: GitHub, https://github.com/Aczarnowska/MS-adverse-events-COVID19.

REFERENCES

1. Sormani MP, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M, et al. COVID-19 Severity in multiple sclerosis: putting data into context. *Neural Neuroimmunol Neuroinflammation*. (2021) 9:e1105. doi: 10.12111/NX1000000000001105
2. Zrzavy T, Kollaritsch H, Rommer PS, Boxberger N, Loebermann M, Wimmer I, et al. Vaccination in multiple sclerosis: friend or foe? *Front Immunol*. (2019) 10:e1883. doi: 10.3389/fimmu.2019.01883
3. McNamara LA, Wiegand RE, Burke RM, Sharma AJ, Sheppard M, Adjemian J, et al. Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data. *Lancet*. (2022) 399:152–60. doi: 10.1016/S0140-6736(21)02226-1
4. Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-biontech and oxford-astrazeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ*. (2021) 373:n1088. doi: 10.1136/bmj.n1088
5. Chen J, Wang R, Gilby NB, Wei G-W. Omicron (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. *ArXiv*. (2021) arXiv:2112.01318v1. doi: 10.1021/acs.jcim.1c01451
6. Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron. *Cell*. (2022) 185:847–59.e11. doi: 10.1016/j.cell.2021.12.28.47333
7. National Multiple Sclerosis Society. COVID-19 Vaccine Guidance for People Living With MS | National Multiple Sclerosis Society. Available online at: https://www.nationalmssociety.org/Coronavirus-Covid-19-Information/Multiple-Sclerosis-and-Coronavirus/Covid-19-Vaccine-Guidance (accessed February 25, 2022).
8. Garg RK, Palival VK. Spectrum of neurological complications following COVID-19 vaccination. *Neural Sci*. (2022) 43:3–40. doi: 10.1007/s10072-021-05662-9
9. Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. *Indian J Clin Biochem*. (2021) 36:427. doi: 10.1007/s12291-021-00968-z
10. Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, et al. COVID-19 vaccination in patients with multiple sclerosis what we have learnt by February 2021. *Multi Scler*. (2021) 27:864–70. doi: 10.1177/13524585211003476
11. Arora G, Taneya J, Bhardwaj P, Goyal S, Naidu K, Yadav SK, et al. Adverse events and breakthrough infections associated with COVID-19 vaccination in the indian population. *J Med Viral*. (2022) 94:3147–54. doi: 10.1002/jmv.27708
12. Menni C, Klasr K, May A, Polodiri L, Capdevilla J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. *Lancet Infect Dis*. (2021) 21:939. doi: 10.1016/S1473-3099(21)00224-3
13. Haas JW, Bender FI, Ballou S, Kelley JM, Wilhelm M, Miller FG, et al. Frequency of adverse events in the placebo arms of COVID-19 vaccine trials: a systematic review and meta-analysis + supplemental content. *JAMA Netw Open*. (2022) 5:2143955. doi: 10.1001/jamanetworkopen.2021.43955
14. Nistri R, Barbuti E, Rinaldi V, Tufano L, Pozzilli V, Iannelli A, et al. Case report: multiple sclerosis relapses after vaccination against SARS-CoV2: a series of clinical cases. *Front Neurol*. (2021) 12:e1866. doi: 10.3389/fneur.2021.765954
15. Dreyer-Alster S, Menascu S, Mandel M, Shirbint E, Magalashvili D, Dolev M, et al. COVID-19 vaccination in patients with multiple sclerosis: safety and humoral efficacy of the third booster dose. *J Neurol Sci*. (2021) 434:120155. doi: 10.1016/j.jns.2021.43555
16. Nojszewska M, Kalinowska A, Adamczyk-Sowa M, Kulakowska A, Bartosik-Psujek H. COVID-19 MRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the section of multiple sclerosis and neuroimmunology of the polish neurological society. *Neural Neurocirch*. (2021) 55:8–11. doi: 10.5603/PJNNS.a2021.0016
17. Wysonge CS, Ndawonde D, Ryan J, Jaca A, Batouré O, Anya BPM, et al. Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future? *Hum Vaccin Immunother*. (2022) 18:1–3. doi: 10.1080/21645515.2021.1893062
18. Brown MT, Benson CA. Addressing the challenges of vaccine hesitancy broadly and related to COVID-19 vaccines. *Top Antivir Med*. (2022) 29:430–9.
19. Wilson SL, Wysonge C. Social media and vaccine hesitancy. *BMJ Glob Heal*. (2020) 5:e004206. doi: 10.1136/bmjgh-2020-004206

ETHICS STATEMENT

The study was approved (approval No. 62/2021) by the Bioethics Committee at Collegium Medicum, Jan Kochanowski University in Kielce, Poland. Written informed consent for participation was not required for this study in accordance with the National Legislation and the Institutional Requirements.

AUTHOR CONTRIBUTIONS

ACz, JT, KK-T, AS, MA-S, HB-P, WB, and AK: conceptualization. ACz, OZ, MW, MM, KN, AJ-W, KR, BL, MP, IR-Z, AP, MS-M, MSI, AG, AW, AJ, MSta, KK, KD, AK-L, WG, AW-H, EK, JC-L, JU, AP-D, MC, AM, JKu, JKo, MB, MSto, KK-B, NN, PW, AP-P, MN, BZ-P, EJ, JZa, MM-J, JZw, BZ, and AP: patient enrollment and data collection. ACz and OZ: formal analysis. ACz, OZ, WB, and AK: methodology. AK: project administration. OZ: software. WB and AK: supervision. ACz: writing—original draft. WB and AK: writing—review & editing. All authors have read and agreed to the published version of the manuscript.
Merck, and Sanofi-Genzyme. AJ received compensation for speaking services from Merck and Sanofi-Genzyme. MS received grant funding from Biogen and received compensation for speaking and consulting services from Biogen, Novartis, Roche, Merck, Sanofi-Genzyme, Bristol Myers Squibb, and Teva. AS, MM, KN, and MW received compensation for speaking and consulting services from Biogen, Novartis, Roche, Merck, Teva, and Sanofi-Genzyme. They received also a grant from NCBIR (nr SZPITALE-JEDNOIMIENNE/18/2020). AK-L received grant funding from Novartis and received compensation for speaking and consulting services from Biogen, Novartis, Roche, Merck, Teva, CSL Behring, Shire, and Sanofi-Genzyme. None of the agreements are relevant to the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Received: 05 April 2022; Accepted: 20 May 2022; Published: 14 June 2022

**Citation:** Czarnowska A, Tarasiuk J, Zajkowska O, Wnuk M, Marona M, Nowak K, Słowik A, Jamroz-Wisniewska A, Rejdak K, Lech B, Popiel M, Rościszewska-Zakowska I, Perenc A, Bartosik-Psujek H, Świederek-Matysiak M, Siger M, Ciach A, Walczak A, Jurkiewicz A, Stasiolek M, Kania K, Dyczewska K, Kalinowska-Lyszczarz A, Galus W, Walawska-Hrycuk A, Krzyzankiewicz J, Ubyt J, Pokrzywko-Dragan A, Kapica-Topczewska K, Chorąży M, Bazyiewicz M, Mironczuk A, Kalikowska J, Kochanowicz J, Białek M, Stolarz M, Kubicka-Bączyk K, Niedziela N, Warmus P, Adamczyk-Sowa M, Podlecka-Piętowska A, Nojszewa A, Zakrzewska-Pniewska B, Jasińska E, Zaborowska J, Milewska-Lędrzeczak M, Zwiernik J, Zwiernik B, Potemkowski A, Brola W and Kalakowska A (2022) Analysis of Side Effects Following Vaccination Against COVID-19 Among Individuals With Multiple Sclerosis Treated With DMTs in Poland. Front. Neurol. 13:913283. doi: 10.3389/fneur.2022.913283

Copyright © 2022 Czarnowska, Tarasiuk, Zajkowska, Wnuk, Marona, Nowak, Słowik, Jamroz-Wisniewska, Rejdak, Lech, Popiel, Rościszewska-Zakowska, Perenc, Bartosik-Psujek, Świederek-Matysiak, Siger, Ciach, Walczak, Jurkiewicz, Stasiolek, Kania, Dyczewska, Kalinowska-Lyszczarz, Galus, Walawska-Hrycuk, Krzyzankiewicz, Ubyt, Pokrzywko-Dragan, Kapica-Topczewska, Chorąży, Bazyiewicz, Mironczuk, Kalikowska, Kochanowicz, Bialek, Stolarz, Kubicka-Bączyk, Niedziela, Warmus, Adamczyk-Sowa, Podlecka-Piętowska, Nojszewa, Zakrzewska-Pniewska, Jasińska, Zaborowska, Milewska-Lędrzeczak, Zwiernik, Zwiernik, Potemkowski, Brola and Kalakowska. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.